Policy Perspectives on Biomarker Testing Coverage for 2024 CANCER BUZZ

As the need for access to guideline-concordant biomarker testing for underserved populations continues to grow, hear what care teams need to know about coverage for Medicaid beneficiaries and the legislative outlook for 2024. In this episode, CANCER BUZZ speaks with Hilary Gee Goeckner, MSW, director of State and Local Campaigns for the American Cancer Society Cancer Action Network (ASC CAN), who shares policy perspectives and the latest on state legislation to expand coverage for biomarker testing for Medicaid beneficiaries. 
 
“There are a lot of challenges around implementation—getting the legislation passed is just the first step…It is also important for providers to be aware of the new rules that affect many plans and their states so they are able to order testing that may not have been covered or rejected previously.” –Hilary Gee Goeckner, MSW
 
Hilary Gee Goeckner, MSW
Director, State and Local Campaigns, Access to Care
American Cancer Society Cancer Action Network
Washington, D.C.
This episode was developed in connection with the ACCC education program Improving Access to Biomarker Testing in Medicaid Populations and is made possible with support by Foundation Medicine and Exact Sciences.
Resources:
The Cost of Biomarker Testing: Moving from Support-Based to Sustainable Solutions 
Comprehensive Cancer Care: The Role of Biomarker Testing 
Biomarker Testing for Medicaid Beneficiaries (Podcast) 
Access to Biomarker Testing - American Cancer Society Cancer Action Network  
The Road to Comprehensive Biomarker Testing for All – ACCC Buzz Blog 
Improving Access to Biomarker Testing in Medicaid Populations 
Precision Medicine in Rural and Underserved Areas – ACCC Buzz Blog 
Patient Perceptions of Biomarker Testing – Oncology Issues 
Cancer Diagnostics - Biomarkers 
Eliminating Precision Medicine Disparities